Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.07.17	Prima BioMed To Get 2nd Milestone Payment From Novartis For IMP701 Program (RTTNews)
16.07.17	Novartis Confirms Positive 5 Year Efficacy And Safety Results For Cosentyx (RTTNews)
14.07.17	Press Release: Novartis confirms 5 year data for -2- (Dow Jones)
14.07.17	Press Release: Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx(R) reinforcing sustained efficacy and safety profile in... (Dow Jones)
13.07.17	MÄRKTE EUROPA: Durchatmen nach Yellen-Rally (Dow Jones)
13.07.17	NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track (RTTNews)
12.07.17	Press Release: Novartis CAR-T cell therapy CTL019 -2- (Dow Jones)
12.07.17	Press Release: Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B... (Dow Jones)
06.07.17	Press Release: Novartis receives approval in the -2- (Dow Jones)
06.07.17	Press Release: Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis (Dow Jones)
29.06.17	Press Release: Novartis receives EU approval for -2- (Dow Jones)
29.06.17	Press Release: Novartis receives EU approval for first-line use of Zykadia(R) in ALK-positive advanced non-small cell lung cancer (NSCLC) (Dow Jones)
29.06.17	Novartis : EU Oks First-line Use Of Zykadia In ALK-positive Advanced NSCLC (RTTNews)
29.06.17	Biotech Stocks Facing FDA Decision In July (RTTNews)
27.06.17	Sandoz Gets EC Approval For Erelzi To Treat Multiple Inflammatory Diseases (RTTNews)
23.06.17	Press Release: NEJM publishes full analysis of -2- (Dow Jones)
23.06.17	Press Release: NEJM publishes full analysis of Rydapt(R) (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) (Dow Jones)
23.06.17	Press Release: Novartis Kisqali(R) (ribociclib) -2- (Dow Jones)
23.06.17	Press Release: Novartis Kisqali(R) (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast ca... (Dow Jones)
23.06.17	Novartis' Kisqali Receives Positive CHMP Opinion (RTTNews)
23.06.17	Press Release: Novartis data shows half of -3- (Dow Jones)
23.06.17	Press Release: Novartis data shows half of -2- (Dow Jones)
23.06.17	Press Release: Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna(R) (Dow Jones)
23.06.17	Press Release: Novartis pivotal CTL019 6-month -2- (Dow Jones)
23.06.17	Press Release: Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL (Dow Jones)
23.06.17	Novartis Announces Results From Addl Analyses Of ENESTfreedom &ENESTop Trials (RTTNews)
23.06.17	Novartis Updates Results From ELIANA Clinical Trial (RTTNews)
23.06.17	Novartis: FDA Approves Tafinlar Plus Mekinist For BRAF V600E-mutant NSCLC (RTTNews)
23.06.17	Press Release: Novartis combination targeted -2- (Dow Jones)
23.06.17	Press Release: Novartis combination targeted therapy Tafinlar(R) + Mekinist(R) receives FDA approval for BRAF V600E mutant metastatic non-small cell lung can... (Dow Jones)
22.06.17	Novartis Moves Notably Higher On Upbeat Heart Drug Trial Results (RTTNews)
22.06.17	MÄRKTE EUROPA/Börsen ohne Schwung - Stada-Übernahme wackelt (Dow Jones)
22.06.17	MÄRKTE EUROPA/DAX pendelt um Nulllinie - Ölsektor belastet Europa (Dow Jones)
22.06.17	MÄRKTE EUROPA/Börsen konsolidieren - Ölsektor belastet (Dow Jones)
22.06.17	Press Release: Novartis Phase III study shows -2- (Dow Jones)
22.06.17	Press Release: Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack (Dow Jones)
22.06.17	Novartis: ACZ885 Phase III CANTOS Study Meets Primary Endpoint - Quick Facts (RTTNews)
21.06.17	Press Release: Novartis achieves important -2- (Dow Jones)
21.06.17	Press Release: Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance (Dow Jones)
21.06.17	Novartis Says EMA Accepts MAA For AMG 334 For Prevention Of Migraine (RTTNews)
20.06.17	Press Release: Novartis RTH258 (brolucizumab) -2- (Dow Jones)
20.06.17	Press Release: Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval (Dow Jones)
20.06.17	Press Release: Novartis real world study shows -2- (Dow Jones)
20.06.17	Press Release: Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden (Dow Jones)
20.06.17	Novartis: RTH258 Meets Endpoints In Two Phase III Studies - Quick Facts (RTTNews)
19.06.17	DURECT's Collaboration with Sandoz Clears HSR Review and is Effective (PR Newswire)
19.06.17	Press Release: Novartis: Sandoz receives approval -2- (Dow Jones)
19.06.17	Press Release: Novartis: Sandoz receives approval in Europe for Rixathon(R) (biosimilar rituximab) to treat blood cancers and immunological diseases (Dow Jones)
17.06.17	Press Release: Novartis International AG: New -2- (Dow Jones)
17.06.17	Press Release: Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Nestle	83.68	6.22 %	K V
Geberit	534.80	4.17 %	K V
Sika	240.40	2.60 %	K V
Givaudan	3’944.00	2.57 %	K V
Holcim	98.24	2.16 %	K V
Lonza Grp	598.00	-0.10 %	K V
Swiss Life Hldg	767.00	-0.21 %	K V
Zurich Insur Gr	569.40	-0.28 %	K V
Swiss Re	141.05	-0.46 %	K V
Swisscom	510.00	-3.04 %	K V

mehr

21.01.25		Novartis-CEO: Trump könnte Entwicklung neuer Medikamente fördern - Novartis-Aktie höher
12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen

21.01.25

Novartis-CEO: Trump könnte Entwicklung neuer Medikamente fördern - Novartis-Aktie höher

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an